| Virus | Prototypical antibody | Similar antibodies | Species | Source, isolation strategy | Epitope,critical residues | Neutralizationpotency | Cross neutralization | References | |
|---|---|---|---|---|---|---|---|---|---|
| Fusion loop | ZIKV-DENV | 2A10G6 | 4G2 | mouse | DENV-2 immunized mouse, hybridoma screening | Fusion loop W101 |
* | ZIKV, DENV1-4, WNV | (17–19) |
| ZIKV-DENV | MZ54 | MZ56 | human | Flavivirus-experienced ZIKV vaccinee, B cell sort using whole virus + ZIKV/DENV E probes | Fusion loop W101 |
** | ZIKV, DENV1-4, WNV | (20) | |
| DI/DII | ZIKV | Z3L1 | human | ZIKV-infected human, memory B cell sort using ZIKV E probe | DI, DI-DII hinge | ** | ZIKV specific | (21) | |
| DENV-1 | 1F4 | human | B cells from DENV immune human, screening of EBV-transformed B cells from total PBMCs | DI, DI-DII hinge | *** | DENV-1 specific | (22, 23) | ||
| DII | ZIKV-DENV | MZ20 | 1C19 | human | Flavivirus-experienced ZIKV vaccinee, B cell sort using whole virus + ZIKV/DENV E probes | DII bc loop R73 |
** | ZIKV, DENV1-4, JEV | (20, 24) |
| E dimer | ZIKV/DENV | EDE1-C8 | EDE1-B10, C10, EDE2-A11 | human | Patients with acute DENV infection, screening of total plasmablasts | E dimer M68, S70, S72, G104, Q253, T315 |
*** (C8) **** (B10) |
ZIKV, DENV1-4 | (25–30) |
| DENV-2 | 2D22 | human | B cells from DENV immune human, screening of EBV-transformed B cells from total PBMCs | E dimer | ** (DENV-2) | DENV-2 specific | (21, 31) | ||
| DIII lateral ridge | ZIKV | ZV-67 | ZV-54 | mouse | ZIKV-infected mouse with EDIII boost, hybridoma screening | DIII lateral ridge K394 |
** | ZIKV specific | (32) |
| ZIKV/DENV-1 | Z004 | Z006, 1C11, ZIKV-116, SMZAb5 | human | B cell from a ZIKV-infected human, memory B cell sort using ZIKV EDIII probe | DIII lateral ridge E393, K394 |
**** | ZIKV, DENV-1 | (33–37) | |
| DENV-1 | E105 | E106 | mouse | DENV-1 infected mouse with EDIII boost, hybridoma screening | DIII lateral ridge | *** | DENV-1 specific | (38) | |
| DENV-2 | 3H5 | 2C8 | mouse | DENV-2 infected mouse, hybridoma screening | DIII lateral ridge | **** | DENV-2 specific | (39, 40) | |
| ZIKV | ZKA190 | human | B cell from a ZIKV-infected human, EBV-transformed B cell from total memory B cells | DI-DIII linker, DIII lateral ridge | *** | ZIKV specific | (41, 42) | ||
| DI/DIII linker | ZIKV/DENV | MZ4 | MZ1, MZ2, MZ24 | human | Flavivirus-experienced ZIKV vaccinee, B cell sort using whole virus + ZIKV/DENV E probes | DI-DIII linker Y305 |
**** | ZIKV, DENV1-4 | (20) |
| DENV-4 | 5H2 | chimpanzee | Phage display from repertoire of infected chimpanzee | DI, DI-DIII linker | ** (DENV-4) | DENV-4 specific | (43, 44) | ||
| Quaternary | ZIKV | ZIKV-117 | human | B cell from a ZIKV-infected human, screening of EBV-transformed B cells from total PBMCs | dimer-dimer interface D67, Q89, K118 |
**** | ZIKV specific | (45, 46) | |
| DENV-3 | 5J7 | human | B cells from DENV immune human, screening of EBV-transformed B cells from total PBMCs | Quaternary DI-DII hinge, DII, DIII on 3 different protomers | **** | DENV-3 specific | (22, 47) |